Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8852W HIGH $2.34
Volume
1.26 M
Value Traded
2.21 M
Short % Float
2.83%
-6.82%Week
-37.88%1 Month
+16.04%3 Month
-9.56%6 Month
-48.84%5 Year
-64.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
142.90 M
EPS (TTM)
-0.28
P/E Ratio
-
Ent. Value
127.86 M
Total Shares
116.18 M
Float Shares
117.01 M
Insiders
3.03%
Institutions
25.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CRDL Catalyst Timeline
Dated clinical, regulatory and corporate events for Cardiol Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cardiol Therapeutics Inc.
200Total events
19Upcoming
27Tier-1 (high impact)
2021 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Enrollment CompleteCardiolRxTrial
MAVERIC achieves original 110-patient enrollment target ahead of schedule
recurrent pericarditissource ↗
▲Equity OfferingCorporate
Received over USD $7 million from exercise of outstanding common share purchase warrants
▼Equity OfferingCorporate
Cardiol files US$150M preliminary base shelf prospectus and Form F-10 registration statement
●Partnership / LicenseCorporate
Material contracts with Dalton Pharma Services, Purisys and ITESM CRO filed concurrently with Shelf Prospectus
▲PublicationCardiolRxPresentation
Phase II MAvERIC-Pilot results published in Journal of the American Heart Association
recurrent pericarditissource ↗
◆Enrollment MilestoneCardiolRxTrial
Phase III MAVERIC trial enrollment approaching completion
recurrent pericarditissource ↗
◆Oral PresentationPresentation
Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference
●Quarterly UpdateCorporate
Released Q1 2026 financial results for three months ended March 31, 2026
▲PublicationCardiolRxPresentation
Phase II MAvERIC results accepted for publication in Journal of the American Heart Association
recurrent pericarditissource ↗
▲Enrollment MilestoneCardiolRxTrial
Phase III MAVERIC trial surpassed 75% enrollment
recurrent pericarditissource ↗
▲Enrollment UpdateCardiolRxTrial
Enrollment surpassed 50% threshold in early January and has now reached 75%
recurrent pericarditissource ↗
◆Oral PresentationPresentation
Live interview with Barchart discussing MAVERIC Phase III trial and ARCHER results
◆Enrollment CompleteCardiolRxTrial
Target recruitment anticipated by end of Q2 2026, with potential extension into Q3
recurrent pericarditissource ↗
▲Full ResultsCardiolRxClinical Data
ARCHER Phase II study results published in ESC Heart Failure
acute myocarditissource ↗
▲Full ResultsCardiolRxClinical Data
Full ARCHER study results published in ESC Heart Failure
acute myocarditissource ↗
▼Equity OfferingCorporate
Closing of bought deal financing and full exercise of over-allotment option for gross proceeds of $14.85 million
▲Enrollment MilestoneCardiolRxTrial
50% patient enrollment milestone in pivotal Phase III MAVERIC trial
recurrent pericarditissource ↗
▼Equity OfferingCorporate
Completed unit financing of 11,423,078 units at $1.30 per unit for gross proceeds of $14,850,001
●Oral PresentationCardiolRxPresentation
Webcast and conference call to discuss ARCHER results
acute myocarditissource ↗
▲Enrollment MilestoneCardiolRxTrial
Surpassed 50% patient enrollment in MAVERIC trial
recurrent pericarditissource ↗
◆Oral PresentationCardiolRxPresentation
Full ARCHER trial results presented at ESC M&PD meeting
acute myocarditissource ↗
▲Full ResultsCardiolRxClinical Data
ARCHER trial results presented at ESC Working Group on Myocardial & Pericardial Disease meeting
acute myocarditissource ↗
▲Patent GrantedCardiolRxIP / Competition
U.S. patent allowance for use of CardiolRx and CRD-38 in treating heart conditions
cardiac disorders including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosissource ↗
▲Patent GrantedCRD-38IP / Competition
U.S. patent allowance for use of CardiolRx and CRD-38 in treating heart conditions
cardiac disorders including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosissource ↗
▲Oral PresentationCardiolRxPresentation
ARCHER results presented at ESC Working Group on Myocardial and Pericardial Disease
acute myocarditissource ↗
▲Patent GrantedIP / Competition
Received U.S. patent allowance protecting CardiolRx and CRD-38 for cardiac conditions through October 2040
cardiac conditionssource ↗
▲PublicationCardiolRxPresentation
ARCHER results published in ESC Heart Failure
acute myocarditissource ↗
▲Full ResultsCardiolRxClinical Data
ARCHER results published in ESC Heart Failure
acute myocarditissource ↗
▲Enrollment UpdateCardiolRxTrial
MAVERIC trial enrollment gaining momentum with several U.S. centers enrolling
recurrent pericarditissource ↗
◆Enrollment UpdateCardiolRxTrial
MAVERIC Phase III trial enrollment gaining momentum with several U.S. centers enrolling
recurrent pericarditissource ↗
▼Equity OfferingCorporate
Completed private placement for total proceeds of approximately $16 million
◆Oral PresentationPresentation
Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
▲Topline ReadoutCardiolRxClinical Data
Topline results from Phase II ARCHER trial of CardiolRx in acute myocarditis
acute myocarditissource ↗
▲Primary Endpoint MetCardiolRxClinical Data
Primary endpoint ECV met with p=0.0538
acute myocarditissource ↗
◆Topline ReadoutCardiolRxClinical Data
Topline results expected within two weeks from database lock
acute myocarditissource ↗
▲Topline ReadoutCardiolRxClinical Data
Reported positive Phase II ARCHER topline results showing significant reduction in left ventricular mass
acute myocarditissource ↗
▲Enrollment CompleteCardiolRxTrial
Database lock for Phase II ARCHER trial of CardiolRx in acute myocarditis
acute myocarditissource ↗
▲Enrollment MilestoneCardiolRxTrial
Initiation of patient enrollment in pivotal Phase III MAVERIC trial
recurrent pericarditissource ↗
▲First Patient DosedCardiolRxTrial
First patient enrolled in pivotal Phase III MAVERIC trial
recurrent pericarditissource ↗
Past FDA Catalysts and PDUFA Decisions
How CRDL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | CardiolRx™ (cannabidiol) oral solution | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$13M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 81%
Micro Cap(rank 535 of 660)
Percentile Rank
Cardiol Therapeutics Inc. faces pipeline headwinds (25/100), with $167M risk-adjusted pipeline value, led by CardiolRx in Acute Myocarditis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CardiolRx Small moleculeNCT05494788 | Recurrent Pericarditis | Phase 3 | COMPLETED | 137 | Sep 6, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRDL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CardiolRx™ Orphan | recurrent pericarditis | Phase 2 | 2026-07-14 | rapid and sustained reductions in pericarditis pain and inflammationRead More | Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart AssociationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRDL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.4 % (33.3 %) | 3.52 M | 3.33 M | 22.02% ( 600.00 K) |
CRDL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRDL ranks across every disease it competes in
Competitive Position is a premium feature
See how CRDL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRDL News
CRDL▼ -6.3%on this news
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Cardiol Therapeutics has successfully reached its Phase III MAVERIC trial enrollment target of 110 patients ahead of schedule and plans to expand this to 150 patients. This decision follows a positive blinded review indicating fewer recurrences of pericarditis than expected. Topline results are now anticipated in mid-2027, with sufficient funding secured to complete the trial.
Read more →CRDLCardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
Cardiol Therapeutics has raised over USD $7 million through the exercise of warrants, enhancing its financial stability as it prepares for the pivotal Phase III MAVERIC trial data readout in recurrent pericarditis. This funding will extend the company's cash runway into H1 2028 and support regulatory preparations for a potential New Drug Application. The CEO emphasized the shareholder confidence reflected in this financial move.
Read more →CRDLCardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission
Cardiol Therapeutics has filed a preliminary base shelf prospectus for up to US$150 million, allowing for potential future offerings of various securities. This filing follows a review by the Ontario Securities Commission, which requested additional disclosures. The company is progressing with its Phase III MAVERIC trial aimed at treating recurrent pericarditis, alongside other promising developments in its pipeline.
Read more →CRDLCardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Cardiol Therapeutics Inc. will participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company is advancing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead drug candidate, CardiolRx™, which has received Orphan Drug Designation from the FDA. The ongoing pivotal Phase III MAVERIC trial is part of their efforts to treat recurrent pericarditis.
Read more →CRDLCardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
Cardiol Therapeutics Inc. will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026. The company focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate, CardiolRx. The ongoing Phase III MAVERIC trial is evaluating CardiolRx for recurrent pericarditis.
Read more →CRDL▲ +8.5%on this news
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
Cardiol Therapeutics announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. The findings demonstrate that CardiolRx™ effectively reduces pericarditis pain and inflammation, supporting the upcoming Phase III MAVERIC trial. Enrollment for this pivotal trial is nearing completion, highlighting significant interest in the treatment.
Read more →CRDLCardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
Cardiol Therapeutics Inc. will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026. The company is advancing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate, CardiolRx™, which has received Orphan Drug Designation from the FDA. This engagement underscores Cardiol's commitment to addressing significant health challenges in cardiology.
Read more →CRDLCardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Cardiol Therapeutics held its Annual General Meeting on June 24, 2026, where shareholders voted in favor of all proposed management resolutions. Key outcomes included the election of several directors and the appointment of BDO Canada LLP as auditors. The company continues to focus on developing therapies for heart disease, including its lead candidate, CardiolRx.
Read more →CRDLCardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
Cardiol Therapeutics Inc. will host its virtual Annual General Meeting (AGM) on June 24, 2026, at 4:30 p.m. EDT. The meeting will be accessible via live webcast. The company is focused on developing therapies for heart disease, including its lead candidate, CardiolRx™, which has received Orphan Drug Designation from the FDA.
Read more →CRDLCARDIOL THERAPEUTICS INC. 602-2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that an annual general meeting (the " Meeting ") of the hol
Cardiol Therapeutics Inc. has announced the schedule for its annual general meeting of shareholders, set to take place on June 24, 2026. Shareholders must return their proxies or votes 48 hours before the meeting. The company is utilizing an online format to facilitate participation and intends to distribute materials through electronic posting, reflecting a move towards sustainable practices. The record date for shareholder eligibility is set for May 7, 2026.
Read more →CRDLCardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
Cardiol Therapeutics Inc. will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, which has received FDA Orphan Drug Designation. The ongoing MAVERIC trial is pivotal for the treatment of recurrent pericarditis.
Read more →CRDLCARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2026 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED) Cardiol Therapeutics Inc. Condensed Interim Consolidated Stateme
Cardiol Therapeutics Inc. reported its condensed interim consolidated financial statements for the three months ending March 31, 2026. The company registered a net loss of 10.82 million CAD, which reflects a significant increase compared to the same period in the previous year. Despite an increase in total assets and cash reserves, total liabilities also rose. The financial outlook indicates challenges as operating expenses remain high, thereby exerting pressure on profitability.
Read more →CRDLCardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics announced that results from its Phase II MAvERIC study on CardiolRx™ for recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association. The findings indicate significant reductions in pain and inflammation, supporting the ongoing Phase III MAVERIC trial, which has exceeded 75% enrollment. The publication underscores the potential of CardiolRx™ as a non-immunosuppressive treatment option.
Read more →CRDLCardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
Cardiol Therapeutics has announced that results from its Phase II MAvERIC study on CardiolRx have been accepted for publication in the Journal of the American Heart Association. The findings suggest that CardiolRx can significantly reduce pain and inflammation in patients suffering from recurrent pericarditis. The positive clinical data supports the ongoing Phase III MAVERIC trial, which has achieved over 75% enrollment. The publication underscores the potential for CardiolRx as a non-immunosuppressive treatment option in managing this condition, addressing a significant unmet medical need.
Read more →CRDLCardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
Cardiol Therapeutics has expanded its MAVERIC Phase III trial network in the U.S., responding to increased interest from major clinical centers. Patient enrollment has surged to 75%, with a target of 110 participants expected by the end of Q2 2026. The trial builds on positive Phase II results and aims to support a New Drug Application with the FDA.
Read more →CRDLCardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Cardiol Therapeutics Inc. announced that CEO David Elsley will participate in a live interview discussing the MAVERIC Phase III trial of CardiolRx™ for recurrent pericarditis and the recently published ARCHER trial results for acute myocarditis. The interview will take place on April 14, 2026, at 12:00 PM EDT. The company is also developing CRD-38 for heart failure.
Read more →CRDLCardiol Therapeutics Announces Year-End 2025 Update on Operations
Cardiol Therapeutics provided a year-end update for 2025, highlighting the initiation of the Phase III MAVERIC trial for recurrent pericarditis and positive Phase II ARCHER results in acute myocarditis. The company advanced its CRD-38 program towards Phase I development and secured a U.S. patent for its therapies. Financially, Cardiol raised $31 million, ensuring funding through 2027.
Read more →About Cardiol Therapeutics Inc.
BIOPHARMAWATCH ELITE PLUS
Trade the next CRDL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime